We are live on ! Find out more

Jaguar Health

JAGX

Market cap $1.9M

3.66 USD

-0.29

7.34%

At close Updated Oct 2, 4:00 PM EDT

Pre-market

After hours

4.31

+0.65

17.76%

1 day

-7.34%

5 days

-47.64%

1 month

-66.58%

3 months

-91.32%

6 months

-98.26%

Year to date

-99.23%

1 year

-99.65%

5 years

-100%

10 years

-100%

About: Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Employees: 47

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 10%

Neutral 65%

Negative 25%

Jaguar Health Announces a Special Stock Dividend

Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").

Jaguar Health Announces a Special Stock Dividend

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026). ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

24/7 Wall Street

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted in company-specific forces.

Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float

Jaguar Health Stock Surges Friday: What's Happening?

Jaguar Health Inc. (NASDAQ:JAGX) shares are surging Friday morning, reversing Thursday's dilution-driven sell-off after the company announced additional debt-for-equity exchanges that reduced its outstanding debt by over $6.7 million and successfully retired a major promissory note.

Jaguar Health Stock Surges Friday: What's Happening?

Jaguar Health Stock Slides Thursday: What's Happening?

Jaguar Health Inc. (NASDAQ:JAGX) shares are sliding Thursday afternoon as equity dilution concerns weigh on the micro-cap biopharmaceutical company following a debt-for-equity exchange.

Jaguar Health Stock Slides Thursday: What's Happening?

24/7 Wall Street

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day's action on the companies themselves rather than on any broader rotation.

Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%

24/7 Wall Street

Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%

Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn't selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.

Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%

Jaguar Health Stock Plunges Wednesday: What's Happening?

Jaguar Health Inc. (NASDAQ:JAGX) shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers.

Jaguar Health Stock Plunges Wednesday: What's Happening?

Jaguar Health Receives Fee Waivers from FDA

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Prescription Drug User Fee Act (PDUFA) for Mytesi ® (crofelemer delayed-release tablets) for the 2027 fiscal year. Mytesi is an FDA-approved prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and is currently commercialized in the U.S. by Future Pak, LLC.

Jaguar Health Receives Fee Waivers from FDA

Jaguar Health, Inc. Announces Reverse Stock Split

Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026 SAN FRANCISCO, CA / ACCESS Newswire / September 15, 2026 / Jaguar Health, Inc. ( Nasdaq:JAGX ) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-15, on Thursday, September 17, 2026 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX".

Jaguar Health, Inc. Announces Reverse Stock Split

See News Rankings

Price charts implemented using Lightweight Charts™